150 completed, 47 unknown, 46 recruiting, 22 terminated. 108 Not applicable, 52 Phase 2, 29 Phase 3, 18 Phase 4, 16 Phase 1.
Follow Alcohol-Induced Disorders: new trials by email Literature Review of Alcohol-Induced Disorders trials Research Report on Alcohol-Induced Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomegranate Dietary Supplements in AUD and ALD Pomegranate Dietary Ssupplement - Alcohol Use Disorder, Alcohol-associated Liver Disease | Not yet recruiting | University of Louisville | 144 | 2027-01-01 | 2026-07-24 | |
| Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group - Intoxication, Delirium Tremens (DTs) | Not applicable | Not yet recruiting | Karolinska Institutet | 50 | 2026-09-30 | 2026-09-23 |
| Elastography-based Brief Alcohol Intervention in Hospitalized Individuals Elastography-based brief alcohol intervention - Alcoholic Liver Disease (ALD), Alcohol Use Disorder | Not applicable | Recruiting | Oslo University Hospital | 500 | 2026-09-14 | 2026-10-22 |
| A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) Efimosfermin alfa, Placebo - Liver Diseases, Alcoholic | Phase 2 | Recruiting | GlaxoSmithKline | 274 | 2026-08-31 | 2026-09-30 |
| Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease PEth Based Contingency Management, PEth Monitoring with Fixed Incentives - Alcohol Use Disorder, Alcohol-associated Liver Disease | Not applicable | Not yet recruiting | Massachusetts General Hospital | 90 | 2026-08-01 | 2026-03-12 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| CARRII Native Intervention Optimization Trial CARRII Native Cores - Fetal Alcohol Spectrum Disorders, Pregnancy | Not applicable | Recruiting | University of Virginia | 512 | 2026-06-02 | 2026-06-23 |
| PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis N-Acetylcysteine (NAC) Treatment, Prednisolone, Placebo of N-acetylcysteine - Alcoholic Hepatitis | Phase 3 | Recruiting | University Hospital, Lille | 477 | 2026-05-22 | 2026-06-01 |
| The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) Palm Tocotrienol Rich Fraction (TRF), Refined, bleached, and deodorised (RBD) palm olein - Alcoholic Fatty Liver Disease | Phase 2 | Not yet recruiting | Universiti Kebangsaan Malaysia Medical Centre | 26 | 2026-05-02 | 2026-04-29 |
| Thrive Person-Centered Planning Program for Young Adults With Fetal Alcohol Spectrum Disorders Thrive Program - Fetal Alcohol Spectrum Disorders | Not applicable | Recruiting | University of Rochester | 60 | 2026-04-14 | 2026-04-30 |
| Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease Individually Targeted rTMS, Conventional rTMS, Transcranial Magnetic Stimulation Sham - Liver Diseases, Alcoholic, Fatty Liver | Not applicable | Not yet recruiting | The Affiliated Hospital of Hangzhou Normal University | 105 | 2026-02-01 | 2026-02-10 |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) Larsucosterol, Placebo - Hepatitis | Phase 3 | Recruiting | Bausch Health Americas, Inc. | 350 | 2026-01-29 | 2026-10-15 |
| Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B Alcohol Consumption - Chronic Hepatitis B, Alcoholic Hepatitis | Completed | Beijing Municipal Administration of Hospitals | 85 | 2025-11-21 | 2026-10-08 | |
| Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial Offer of specialized alcohol use disorder treatment in the hepatology clinic - Liver Diseases, Alcoholic, Alcohol Use Disorder | Not applicable | Recruiting | Zealand University Hospital | 221 | 2025-11-15 | 2025-11-18 |
| LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis TREM-1 expression (via immunohistochemistry) between SAH patients and controls - Severe Alcoholic Hepatitis | Not yet recruiting | Central Hospital, Nancy, France | 300 | 2025-10-01 | 2025-09-16 | |
| Long-term Sustainability of the Effects of Dog-Assisted Therapy in Children and Adolescents With Fetal Alcohol Spectrum Disorder: a 12-month Longitudinal Study Dog assisted therapy - Fetal Alcohol Effect, Fetal Alcohol Syndrome | Not applicable | Active not recruiting | Hospital Universitari Vall d'Hebron Research Institute | 55 | 2025-09-01 | 2026-07-21 |
| Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis Self-Efficacy, Health Literacy | Recruiting | Hannover Medical School | 200 | 2025-08-11 | 2025-09-11 | |
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | Not applicable | Recruiting | Phenomen Pharma | 90 | 2025-06-19 | 2025-07-23 |
| Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease HepQuant DuO Test - Alcoholic Hepatitis, Alcohol-related Liver Disease | Recruiting | HepQuant, LLC | 40 | 2025-06-10 | 2026-09-16 | |
| Dose Escalation Study of Vinpocetine in Healthy Volunteers Vinpocetine - Fetal Alcohol Spectrum Disorders | Phase 1 | Not yet recruiting | Stanford University | 20 | 2025-06-01 | 2024-10-10 |
Showing 20 of 299. Sign in to see all of them.
Hepatitis, Alcoholic (107) · Liver Diseases, Alcoholic (73) · Fetal Alcohol Spectrum Disorders (65) · Liver Cirrhosis, Alcoholic (43) · Alcoholism (36) · Fibrosis (28) · Liver Cirrhosis (24) · Liver Diseases (17) · Non-alcoholic Fatty Liver Disease (13) · Alcohol Withdrawal Delirium (11) · Hepatitis (8) · Carcinoma, Hepatocellular (7) · Alcohol-Related Disorders (6) · Attention Deficit Disorder with Hyperactivity (6)
Chemically-Induced Disorders (299) · Substance-Related Disorders (297) · Alcohol-Related Disorders (293) · Digestive System Diseases (211) · Liver Diseases (190) · Liver Diseases, Alcoholic (132) · Hepatitis (107) · Pathological Conditions, Signs and Symptoms (94) · Pathologic Processes (87) · Urogenital Diseases (73) · Female Urogenital Diseases and Pregnancy Complications (71) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (68) · Fetal Diseases (65) · Pregnancy Complications (64)
Prednisolone (11) · Ethanol (9) · Pentoxifylline (9) · Blood Specimen Collection (7) · Granulocyte Colony-Stimulating Factor (7) · Acetylcysteine (6) · Choline (6) · Baclofen (5) · Fecal Microbiota Transplantation (5) · Liver Transplantation (4) · Prednisone (4) · Probiotics (4) · Standard of Care (4) · Adrenal Cortex Hormones (3) · Cognitive Training (3)
Institute of Liver and Biliary Sciences, India (11) · University of Rochester (9) · University Hospital, Lille (8) · Erasme University Hospital (7) · University of Aarhus (7) · Assistance Publique - Hôpitaux de Paris (6) · Indiana University (6) · The Cleveland Clinic (6) · University of Oklahoma (6) · Chuncheon Sacred Heart Hospital (5) · Pharmicell Co., Ltd. (5) · Post Graduate Institute of Medical Education and Research, Chandigarh (5) · Centers for Disease Control and Prevention (4) · Hospital Universitari Vall d'Hebron Research Institute (4) · Mayo Clinic (4)
United States (117) · France (38) · India (22) · Denmark (19) · United Kingdom (18) · South Korea (14) · Canada (12) · Spain (11) · Belgium (10) · China (7) · Germany (6) · Australia (4) · Finland (4) · Italy (4) · Mexico (4)
Jeffrey R Wozniak, Ph.D. (4) · Michael J Vinikoor, MD (3) · Arnaud Lemmers, MD (2) · Christophe Moreno, MD, PhD (2) · Craig J McClain, MD (2) · Hanna Kahila, MD (2) · Karen S Ingersoll, Ph.D. (2) · Ki Tae Suk, PhD (2) · Moonyoung Kim (2) · Naga Chalasani, MD (2) · Philippe Mathurin, MD,PhD (2) · Robert S Brown, MD, MPH (2) · Santiago Tome, MD (2) · Soon Koo Baik, M.D.,Ph.D (2) · Srinivasan Dasarathy, MD (2)
PMID 37011138, PMID 31811953, PMID 35084335, PMID 38215876, PMID 39956364, PMID 11605686, PMID 11943418, PMID 14647046, PMID 15122768, PMID 1531090, PMID 15618643, PMID 15763232, PMID 16026887, PMID 17204261, PMID 17518367, PMID 18068515, PMID 18218147, PMID 18270828, PMID 19058754, PMID 19177575, PMID 19445945, PMID 19459039, PMID 19553649, PMID 19560604, PMID 20334708, PMID 20375733, PMID 20561703, PMID 20944765, PMID 20951277, PMID 21085006, PMID 21334404, PMID 21838526, PMID 22044287, PMID 22070475, PMID 22251828, PMID 22821948, PMID 22898443, PMID 23192220, PMID 23294846, PMID 23435303, PMID 23737845, PMID 23763608, PMID 23782511, PMID 23810264, PMID 23855300, PMID 23870864, PMID 23939511, PMID 24026598, PMID 24029409, PMID 24523762
U01AA026104 (3), 2025 (2), P50AA027054 (2), R01AA016234 (2), R01AA024123 (2), U01AA021788 (2), U01AA021840 (2), U01AA021886 (2), U01AA021891 (2), U01AA021893 (2), U24DK130164 (2), 2004 (1), 2014 (1), 2016 (1), F31AA031596 (1)